Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (OTCQB: PRVCF) is a health sciences company that regularly issues news on its preventive and curative therapy programs, corporate developments and proposed corporate transactions. Company news provides insight into its research pipeline, including dual gene therapy for diabetes and obesity, the Sol-Gel nose-to-brain (N2B) delivery platform, Nature Identical™ peptide programs, nonaddictive analgesic peptide candidates and concussion-related therapeutic concepts.
Recent announcements have highlighted appointments of experienced scientific and industry advisors, such as corporate advisors and technology leaders who bring backgrounds in drug discovery, metabolic disease research, molecular genetics and clinical development. These updates help investors and observers understand how PreveCeutical is building expertise around its programs and advancing toward development and potential commercialization.
News releases also cover the evolution of the Sol-Gel N2B platform, including a program aimed at delivering dopamine and/or its precursor L-Dopa directly to the brain in the context of Parkinson’s disease. The company has described this platform as designed to bypass the blood-brain barrier, with the goal of improving drug bioavailability and reducing systemic side effects.
Another recurring theme in PreveCeutical’s news is its relationship with BioGene Therapeutics Inc., a wholly owned subsidiary focused on metabolic health and gene-based treatments. The company has announced a proposed plan of arrangement under which it intends to distribute up to 12,000,000 BioGene common shares to PreveCeutical shareholders, and meeting materials and court orders related to this arrangement have been reported in its news flow.
Investors and researchers following PRVCF news can use this page to review updates on research milestones, advisory and executive appointments, meeting dates, and the progress of the proposed BioGene share distribution, all drawn from official company announcements.
PreveCeutical Medical (OTCQB: PRVCF) has scheduled its annual general and special meeting for August 15, 2025. Shareholders will vote on director elections, auditor appointments, and notably, a plan to distribute up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders.
The arrangement will result in shareholders owning stakes in two separate companies: BioGene, focusing on Dual Gene Therapy program development, and PreveCeutical, continuing its focus on preventive and curative therapies using organic products. This strategic separation aims to expand both companies' shareholder bases and improve access to capital for research and development.
PreveCeutical Medical (OTCQB: PRVCF) has appointed Stephen Glover as Corporate Advisor, effective May 24, 2025. The health sciences company, which focuses on developing innovative preventive and curative therapies using organic and nature-identical products, expects to benefit from Glover's extensive experience in biopharma, corporate strategy, commercialization, and financial management. CEO Stephen Van Deventer emphasized Glover's proven leadership and track record in building and transforming organizations as key assets for advancing PreveCeutical's therapeutic development mission.
PreveCeutical Medical Inc. (PRVCF) has announced the launch of a new website for its majority-owned subsidiary, BioGene Therapeutics Inc., a Texas-based life sciences company. The website aims to showcase BioGene's research and development initiatives, particularly focusing on metabolic health and gene-based treatments.
Through its wholly-owned subsidiary BioGene Australia, the company is conducting research on GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies targeting the global diabetes and obesity crisis. The website launch is part of BioGene's growth strategy to enhance stakeholder communication and industry engagement.
PreveCeutical Medical Inc. (PRVCF) has announced a new program to develop their Nose to Brain (N2B) Sol-Gel platform for delivering Dopamine and L-Dopa directly to the brain for Parkinson's disease treatment. The technology is designed to bypass the Blood Brain Barrier (BBB), which could potentially improve drug bioavailability while reducing side effects associated with current delivery methods.
The company expects this approach to enhance safety and effectiveness by avoiding systemic exposure and requiring lower therapeutic doses through direct brain targeting. The N2B platform's ability to bypass other body compartments could lead to reduced drug dosages and improved patient compliance.
PreveCeutical plans to demonstrate proof of concept in preclinical models before seeking partnerships with organizations specializing in Parkinson's disease.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has appointed Dr. Bryan Jones as Director of Sol-Gel Special Projects, effective January 31, 2025. Dr. Jones brings over 30 years of drug development experience and currently serves as Chief Operating Officer of Aardvark Therapeutics. His extensive background includes co-founding Sollis Therapeutics and Sherrington Pharmaceuticals, with experience at Bristol-Myers Squibb and work on products like Cialis.
Dr. Jones holds a Ph.D. in Genetics from the University of Washington and will focus on advancing PreveCeutical's Sol-Gel program for Nose to Brain delivery of therapeutics. The company aims to develop preventive and curative therapies using organic and nature identical products. CEO Stephen Van Deventer expressed that Dr. Jones's expertise will help accelerate the program, with details on their first targeted therapeutic forthcoming.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced that its subsidiary BioGene Therapeutics will participate in the 43rd JP Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.
The company's leadership team attending includes Dr. Harry Parekh (Chief Research Officer & Scientific Founder), along with board members Dr. Deepak Sampath, Steve Glover, and Patroski J. Lawson. BioGene, under parent company PreveCeutical, focuses on developing innovative preventive and curative therapies using organic and nature-identical products.
CEO Stephen Van Deventer emphasized the importance of having their Scientific Founder and experienced team members present to showcase their accomplishments and future plans. Interested parties can request meetings with the team via info@biogenetherapeutics.com.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has announced a change in its auditing firm. The company's board of directors has accepted the resignation of Smythe LLP as their former auditor and appointed Davidson & Company LLP as the successor auditor, effective December 18, 2024. The new auditor will serve until the company's next annual general meeting of shareholders.
The company confirms there were no reservations in the former auditor's reports during their tenure, and no reportable events exist between PreveCeutical and Smythe LLP. The required documentation, including the Notice of Change of Auditor and letters from both auditing firms, has been reviewed by the audit committee and board of directors and will be filed on SEDAR.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Patroski J. Lawson as an independent director effective December 6, 2024. According to CEO Stephen Van Deventer, Lawson brings extensive experience in government affairs across local, state, federal, and global levels, particularly within the healthcare sector. The company expects his strategic insights and leadership to strengthen their governance and advocacy efforts as they navigate the regulatory landscape in developing innovative therapies.
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Barry Ticho to its Scientific Advisory Board effective December 1, 2024. Dr. Ticho brings over 25 years of biopharma and drug development expertise, currently serving as Chief Medical Officer at Stoke Therapeutics. His experience includes co-founding Verve Therapeutics and leading R&D initiatives at Moderna Therapeutics, Pfizer, and Biogen.
Dr. Ticho has notably transformed Stoke from a 9-employee private company to a publicly traded organization with over 100 employees, focusing on genetic diseases in neurology and ophthalmology. He holds an MD and PhD from the University of Chicago and serves on multiple Scientific Advisory Boards including Cardior Pharmaceuticals, Mana.bio, and Sania.